BioSpace News Archive

A new analysis finds that every state in the nation is at risk for higher than normal premium increases due to continued policy changes and uncertainty at the federal level.

Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year Delivered $0.4M Full-year Profit on a Non-GAAP Basis Excluding Business Development Transaction Costs Delivered 7 Percent Test Growth and 6 Percent Revenue Growth in the Fourth Quarter Guides to Double-digit Revenue Growth and Full-year Profitability in 2018

Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.

Novoheart is pleased to announce that it has published a comprehensive study of the world’s first human heart-in-a-jar, in the prestigious bioengineering journal Biomaterials.

LivaNova PLC announced that it has entered into a definitive Stock and Asset Purchase Agreement to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation.

Portage will invest US$950,000 by subscribing to an unsecured, one-year convertible loan instrument.

Dr. Materna’s experience in product and business strategy in the field of metagenomics and infectious disease genomics will fuel the strategic expansion of the product portfolio and the growth of CosmosID.

Full Year CRINONE® Revenues Increased 20% and Juniper Pharma Services (JPS) Revenues Increased 32% Year-over-Year Ended 2017 Cash Flow Positive; Company Expects Trend to Continue in 2018 Conference Call at 8:30 a.m. EST Today

DEXTENZA™ New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) remains on track for the first half of 2018